^
    Back
    Association details:
    Biomarker:PSMD4 amplification
    Cancer:Breast Cancer
    Drug:Talzenna (talazoparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Genes Chromosomes Cancer
    Title:

    Proteasome ubiquitin receptor PSMD4 is an amplification target in breast cancer and may predict sensitivity to PARPi

    Excerpt:
    Conversely, we find that breast cancer cell lines that have copy number gain or amplification for PSMD4 are significantly more sensitive to talazoparib.
    DOI:
    10.1002/gcc.22459